BNC210 is a new drug in phase 2 trials for multiple anxiety disorders. It has a novel mechanism of action that has not been seen before in other drugs.

According to the company, it’s a negative allosteric modulator of the alpha 7 nicotinic acetylcholine recepter, and has a similar effect on anxiety as benzos, but without the side effects or addiction potential.

https://www.bionomics.com.au/pipeline/bnc210/